Iregene Therapeutics
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. Our leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2. We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
5
51 to 200 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Iregene Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
Showing 1 of 3 verified contacts
Top roles at Iregene Therapeutics
3 distinct titles indexed · top 3 shown.
- 1ceo
- 1chief medical officer
- 1finance director and board secretary
Sign up to unlock all 3 contacts at Iregene Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Iregene Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.